Cyagen (Guangzhou) Biosciences Co., Ltd.

Cyagen Biosciences Group is a leading diversified multinational biotechnology entity, founded in the United States in 2006, with its China headquarters in Guangzhou. It currently has branches and offices in Suzhou, Beijing, Shanghai, Wuhan, Chongqing, and other cities. The company employs over 400 staff and has a total facility area exceeding 22,000 square meters. Its main business consists of two major platforms: the Model Animal Platform and the Cell Biology Platform. The ISO9001:2015 and AAALAC International accreditations ensure that all products and technical services provided to researchers meet international standards. Adhering to the corporate vision of "Creating Infinite Possibilities for Biotechnology," Cyagen Biosciences has established extensive collaborations with tens of thousands of scientists in over 100 countries and regions. Its products and technologies have been directly applied in more than 2,700 academic papers, including those published in the top three journals CNS (Cell, Nature, Science).

Model Animal Platform
Cyagen's Model Animal Research Center boasts a 15,000 square meter experimental animal center and a 10,000 square meter SPF-grade animal laboratory, equipped with over 500 sets of IVC housing equipment, capable of housing more than 60,000 cages of SPF-grade mice and rats, with a breeding population exceeding 250,000 animals. It can construct over 10,000 gene knockout mouse and transgenic mouse models annually. In 2016, TurboKnockout advanced the gold standard of ES targeting to a new level; in the same year, CRISPR-Pro made large-fragment knock-in and conditional knockout more efficient. In early 2017, the AlphaKnockout gene targeting expert system achieved the first AI-based optimal solution design; in July of that year, it launched a sperm bank with ten thousand CRISPR-AI knockout mouse models. Over the past thirteen years since its establishment, Cyagen Biosciences has been committed to technological innovation, and through persistent efforts, it has steadily become one of the world's leading and most recognized commercial platforms for genetically engineered model animals.

Cell Biology Platform
As a research stem cell supplier with 13 years of history, Cyagen possesses a comprehensive research stem cell bank, having independently developed over a hundred stem cell and primary cell products. The dozens of research stem cell standards independently drafted have become one of the internationally referenced stem cell technology standards. Cyagen's stem cells, primary cells, and related culture media have served tens of thousands of customers, achieving a win-win in market share and customer satisfaction.

Cyagen's professional and comprehensive cell technology platform has a 5,000 square meter cell biology laboratory, equipped with complete experimental instruments and a first-class expert team. It has established a standard quality control system for services related to stem cells, tumor cells, and stable cell line services. Its stem cell induced differentiation services and stable cell line construction services have helped thousands of researchers solve scientific problems.